uniQure
Update in progressQURE (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
uniQure N.V. develops gene therapy treatments for rare and devastating diseases in the United States. It offers HEMGENIX for hemophilia B to enable factor IX production and reduce bleeding risk. Lead candidate AMT-130 targets Huntington’s disease in Phase I/II, while AMT-260 targets mesial temporal lobe epilepsy (Phase I/IIa). AMT-162 targets SOD1-ALS and AMT-191 Fabry disease, both in Phase I/IIa. It licenses intrathecal ALS programs from Apic Bio and has a supply agreement with CLS Bhering. Founded in 1998, based in Amsterdam.
Company score
- Sentiment
- -0.21
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- -0.17
- Governance
- -0.14
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- -0.08
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- -0.15
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!